MXPA02003496A - Derivados de piridinio para el tratamiento de complicaciones vasculares diabeticas y relacionadas con la edad. - Google Patents

Derivados de piridinio para el tratamiento de complicaciones vasculares diabeticas y relacionadas con la edad.

Info

Publication number
MXPA02003496A
MXPA02003496A MXPA02003496A MXPA02003496A MXPA02003496A MX PA02003496 A MXPA02003496 A MX PA02003496A MX PA02003496 A MXPA02003496 A MX PA02003496A MX PA02003496 A MXPA02003496 A MX PA02003496A MX PA02003496 A MXPA02003496 A MX PA02003496A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
oxoethyl
pyridinium
acceptable salt
bromide
Prior art date
Application number
MXPA02003496A
Other languages
English (en)
Spanish (es)
Inventor
Sankaranarayanan Alangudi
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of MXPA02003496A publication Critical patent/MXPA02003496A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA02003496A 1999-10-06 1999-10-15 Derivados de piridinio para el tratamiento de complicaciones vasculares diabeticas y relacionadas con la edad. MXPA02003496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN827CA1999 1999-10-06
PCT/IB1999/001687 WO2001025209A1 (en) 1999-10-06 1999-10-15 Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications

Publications (1)

Publication Number Publication Date
MXPA02003496A true MXPA02003496A (es) 2005-06-20

Family

ID=11084921

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003496A MXPA02003496A (es) 1999-10-06 1999-10-15 Derivados de piridinio para el tratamiento de complicaciones vasculares diabeticas y relacionadas con la edad.

Country Status (12)

Country Link
EP (1) EP1220843A1 (cs)
JP (1) JP2003511370A (cs)
CN (1) CN1329597A (cs)
AU (1) AU5994499A (cs)
BR (1) BR9915962A (cs)
CA (1) CA2351075A1 (cs)
CZ (1) CZ20011808A3 (cs)
HK (1) HK1044336A1 (cs)
HU (1) HUP0301687A2 (cs)
MX (1) MXPA02003496A (cs)
PL (1) PL348049A1 (cs)
WO (1) WO2001025209A1 (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067851A2 (en) * 2000-12-29 2002-09-06 Alteon, Inc. Method for treating fibrotic diseases or other indications iiic
ATE299496T1 (de) * 2001-03-21 2005-07-15 Torrent Pharmaceuticals Ltd Pyridiniumverbindungen zur behandlung von age- relatierten krankheiten
CZ303214B6 (cs) * 2001-03-21 2012-05-30 Torrent Pharmaceuticals Ltd Pyridiniová sloucenina, zpusob její výroby, její použití, farmaceutický prostredek ji obsahující, zpusob jeho výroby a jeho použití
ES2231685T3 (es) * 2001-04-05 2005-05-16 Torrent Pharmaceuticals Ltd Compuestos heterociclicos para complicaciones vasculares diabeticas y relacionadas con la edad.
HUP0104832A2 (en) * 2001-10-19 2003-08-28 Torrent Pharmaceuticals Ltd Cosmetic composition and method
GB0328314D0 (en) * 2003-12-05 2004-01-07 Univ Bath Therapeutics
WO2007132179A2 (en) * 2006-05-15 2007-11-22 University Of Bath Therapeutics comprising pyridinium derivatives
JP2009155315A (ja) * 2007-12-26 2009-07-16 Fujiyakuhin Co Ltd 注射剤
KR20120018185A (ko) * 2009-05-07 2012-02-29 토렌트 파마슈티칼스 리미티드 당뇨병 치료에 유용한 피페리딘 유도체
EP2903614B1 (en) * 2012-10-05 2021-09-29 Sphaera Pharma Pte. Ltd Novel compounds, their synthesis and their uses
EP3280711A1 (en) * 2015-04-08 2018-02-14 Torrent Pharmaceuticals Limited Novel pyridinium compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH335521A (de) * 1955-06-02 1959-01-15 Cilag Ag Verfahren zur Herstellung neuer quaternärer Salze
US3318787A (en) * 1964-02-07 1967-05-09 Udylite Corp Electrodeposition of zinc
US3823076A (en) * 1972-05-23 1974-07-09 Du Pont Zinc electroplating additive
JPS5936247B2 (ja) * 1977-04-20 1984-09-03 ティーディーケイ株式会社 電気的表示装置
JPS55138742A (en) * 1979-04-17 1980-10-29 Fuji Photo Film Co Ltd Silver halide emulsion developing method
JPH0253759A (ja) * 1988-08-18 1990-02-22 Hamari Yakuhin Kogyo Kk 新規な4級アンモニウム化合物
DD275872A1 (de) * 1988-09-27 1990-02-07 Univ Dresden Tech Verfahren zur herstellung von 5h-pyrido[1',2':1,2]imidazo[5,4-c]chinolin-6-onen
MX9705449A (es) * 1995-01-18 1998-02-28 Alteon Inc Uso de compuestos de tiazolio para evitar y revertir la formacion de productos finales de glicosilacion avanzada.
CA2285556A1 (en) * 1997-04-04 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds

Also Published As

Publication number Publication date
AU5994499A (en) 2001-05-10
PL348049A1 (en) 2002-05-06
CA2351075A1 (en) 2001-04-12
HK1044336A1 (zh) 2002-10-18
JP2003511370A (ja) 2003-03-25
WO2001025209A1 (en) 2001-04-12
EP1220843A1 (en) 2002-07-10
BR9915962A (pt) 2003-01-07
HUP0301687A2 (hu) 2003-08-28
CN1329597A (zh) 2002-01-02
CZ20011808A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
CN100435785C (zh) 抑制iapp的化合物或其可药用酯或其可药用盐的制药应用
CA2029420C (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
US6624178B2 (en) Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
CZ20032013A3 (cs) Heterocyklické sloučeniny pro léčení vaskulárních diabetických komplikací a komplikací souvisejících se stářím
MXPA02003496A (es) Derivados de piridinio para el tratamiento de complicaciones vasculares diabeticas y relacionadas con la edad.
HRP20010584A2 (en) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
CZ20014034A3 (cs) Kosmetický prostředek, způsob a prostředek a vychytávání volných radikálů z těla buněk
US6608094B2 (en) Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
CN114390924A (zh) 用于蛋白质降解的化合物、组合物和方法
WO1995021822A1 (en) Pyridinium compounds
JP4471141B2 (ja) 老化関連及び糖尿病脈管合併症の管理のための新規化合物、その製造方法及び治療的使用
JP2000500465A (ja) 血液調節化合物
KR101889050B1 (ko) 철 결핍 증상 및 철 결핍성 빈혈의 치료 및 예방용 Fe(III) 착화합물
US4880821A (en) α-nitroalkylnitrobenzenesulfonamides
JPH10101566A (ja) 網膜保護剤
CA2859156C (en) Treatment of type i and type ii diabetes
JPH10507446A (ja) ビス−2−アミノピリジン類、その製造方法及び寄生虫感染を制御するためのその用途
EP2714030B1 (de) Fe(iii)-2,4-dioxo-1-carbonyl-komplexverbindungen zur verwendung bei der behandlung und der prophylaxe von eisenmangelerscheinungen und eisenmangelanämien
KR20140143832A (ko) 철 결핍 증상 및 철 결핍 빈혈의 치료 및 예방을 위한 Fe(III)-피라진 착화합물
JPH03261772A (ja) チアゾリジン系化合物およびこれを含有するグリケーション阻害剤
CZ20011032A3 (cs) Pyridinová sloučenina, způsob její výroby, její pouľití, farmaceutický prostředek ji obsahující, způsob jeho výroby a jeho pouľití
AU3137601A (en) Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses
AU8936901A (en) Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications